Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous Leukemia and Myelodysplastic Syndrome: Initial Results of a Phase I Trial-Reference-Cited by-同舟云学术

Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous Leukemia and Myelodysplastic Syndrome: Initial Results of a Phase I Trial

Published:1993-01 Issue:4 Volume:3 Page:383-390
ISSN:1050-5261
Container-title:Antisense Research and Development
language:en
Short-container-title:Antisense Research and Development

Author:

BAYEVER ELIEL,IVERSEN PATRICK L.,BISHOP MICHAEL R.,SHARP J. GRAHAM,TEWARY HEMANT K.,ARNESON MARK A.,PIRRUCCELLO SAMUEL J.,RUDDON RAYMOND W.,KESSINGER ANNE,ZON GERALD,ARMITAGE JAMES O.

Publisher

Mary Ann Liebert Inc

Subject

Genetics

Link

http://www.liebertpub.com/doi/pdf/10.1089/ard.1993.3.383

Reference14 articles.

1. Separation of synthetic phosphorothioate oligodeoxynucleotides from their oxygenated (phosphodiester) defect species by strong-anion-exchange high-performance liquid chromatography

2. Self-renewal in culture of proliferative blast progenitor cells in acute myeloblastic leukemia

3. Contributions of host- and disease-related attributes to the outcome of patients with acute myelogenous leukemia.

4. Production of leukemic blast growth factor by a human bladder carcinoma cell line

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CpG oligonucleotides induce acute murine thrombocytopenia dependent on toll-like receptor 9 and spleen tyrosine kinase pathways;Journal of Thrombosis and Haemostasis;2024-08

2. Stargardt disease-associated in-frame ABCA4 exon 17 skipping results in significant ABCA4 function;Journal of Translational Medicine;2023-08-16

3. Introduction and History of the Chemistry of Nucleic Acids Therapeutics;Methods in Molecular Biology;2022

4. Advances in gene therapy for neurogenetic diseases: a brief review;Journal of Molecular Medicine;2021-11-27

5. Antisense therapies for movement disorders;Movement Disorders;2019-07-08